ALPS Group Inc.

20/04/2026

Less than six months after its Nasdaq debut, ALPS Group is shifting its focus toward addressing a key challenge in healthcare—bridging the gap in access to biotechnology.

As reported by The Business Times, this pivot reflects the group’s evolving strategy to expand accessibility and support broader adoption of advanced healthcare solutions across markets.

This marks an important step in aligning innovation with real-world healthcare needs.

It is expanding into insurance and education to rebuild valuation and put advanced treatments within reach for more people Read more at The Business Times.

17/04/2026

Alps Group Inc has appointed a former Ernst & Young partner, Hee H. Lee, to its Board of Directors — bringing over 35 years of global financial, advisory, and capital markets expertise to the table.

This strategic appointment reinforces the Group’s commitment to transparency, accountability, and long-term value creation as it continues to scale in the precision medicine and biotech space.

https://uk.finance.yahoo.com/news/alps-group-appoints-former-ernst-123000257.html

KUALA LUMPUR, Malaysia, April 17, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the “Company” or “Alps Group”), the parent company of Alps Life Sciences Inc. (“Alps Holdco”), a biotechnology research and healthcare platform focused on predictive, preventive, and precision medicine, announced ...

24/02/2026

ALPS Group Inc publishes clinical safety, tolerability & effectiveness data advancing its autologous NK cell pipeline using an in-house culture protocol. A key milestone in scalable immune cell therapy.

Read more: https://finance.yahoo.com/news/alps-group-inc-publishes-clinical-130000519.html

https://alps-holdings.com/alps-group-inc-publishes-clinical-safety-tolerability-and-effectiveness-data-supporting-advancement-of-its-autologous-nk-cell-pipeline-using-an-in-house-developed-culture-protocol/

KUALA LUMPUR, Malaysia, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the “Company” or “Alps Group”), the parent company of Alps Life Sciences Inc. (“Alps Holdco”), a fully integrated biotechnology research and healthcare platform specializing in predictive, preventive, and precision...

16/02/2026

Wishing you health, prosperity, and happiness this Chinese New Year. 🧧✨

09/02/2026

Alps Group Inc announces a potential expansion of its exosome pipeline beyond CELESOME(+), following peer-reviewed clinical observations of nebulized hUCMSC-derived exosomes in asthma and COPD patients.

KUALA LUMPUR, Malaysia, Jan. 30, 2026 (GLOBE NEWSWIRE) — Alps Group Inc (the “Company” or “Alps Group”), the parent company of Alps Life Sciences Inc. (“Alps Holdco”), a fully integrated biotechnology research and healthcare platform specializing in predictive, preventive, and precisio...